September has seen the debut of generic versions of Celgene’s blockbuster Revlimid (lenalidomide) capsules in Canada, with both Dr Reddy’s and Natco announcing launches of their own versions of the multiple myeloma treatment, after having previously settled related Canadian litigation with the originator, now part of Bristol Myers Squibb.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?